Connor, Clark & Lunn Investment Management (CC&L)’s Rhythm Pharmaceuticals RYTM Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.27M | Buy |
115,118
+64,561
| +128% | +$4.08M | 0.03% | 484 |
|
|
2025
Q1 | $2.68M | Buy |
50,557
+44,468
| +730% | +$2.36M | 0.01% | 659 |
|
|
2024
Q4 | $341K | Buy |
+6,089
| New | +$341K | ﹤0.01% | 1235 |
|
|
2024
Q3 | – | Sell |
-9,340
| Closed | -$384K | – | 1617 |
|
|
2024
Q2 | $384K | Sell |
9,340
-335
| -3% | -$13.8K | ﹤0.01% | 1121 |
|
|
2024
Q1 | $419K | Sell |
9,675
-55,869
| -85% | -$2.42M | ﹤0.01% | 1175 |
|
|
2023
Q4 | $3.01M | Sell |
65,544
-66,118
| -50% | -$3.04M | 0.01% | 564 |
|
|
2023
Q3 | $3.02M | Buy |
131,662
+73,543
| +127% | +$1.69M | 0.02% | 513 |
|
|
2023
Q2 | $958K | Buy |
+58,119
| New | +$958K | ﹤0.01% | 807 |
|
|
2022
Q3 | – | Sell |
-11,225
| Closed | -$47K | – | 1233 |
|
|
2022
Q2 | $47K | Buy |
+11,225
| New | +$47K | ﹤0.01% | 1008 |
|